46 results about "Pharmasolve" patented technology

The invention relates to a cerebral apoplexy treating effervescence tablet and its preparation method, wherein the formula of the preparation comprises dried cerebral thrombus-treating concrete powder, cross bonding polyvinylpyrrolidone, mannitol, waterless lemon acid, sodium hydrogen carbonate, crystalline cellulose, miropowdered silica gel, magnesium stearate, talcum powder and Aspartame. The preparation employs a direct tabletting method, the bioavailability of the medicament can be improved, and the invention also has the advantages of convenient administration, reduced irritation to esophagus and gastrointestinal tract.

The invention discloses a fullerene color-changing lipstick and a preparation method thereof, and relates to the technical field of skin care products. The fullerene color-changing lipstick includes the following components in parts by weight: 10-15 parts of water, 3-6 parts of white beeswax, 1-3 parts of candelilla wax, 4-6 parts of polyethylene, 2-4 parts of polyisobutylene, 1-2 parts of bis-diglyceryl polyacyladipate-2, 2-7 parts of phytosteryl oleate, 7-10 parts of ethylhexyl palmitate, 12-15 parts of cetyl ethyl hexanoate, 18-25 parts of polyglyceryl-2 diisostearate, 8-12 parts of ozokerite, 0.1-1 part of caprylyl glycol, 15-18 parts of polyglyceryl-2 triisostearate, 0.1-0.2 part of fullerene, 0.1-0.15 part of polyvinylpyrrolidone, 5-7 parts of butanediol, 2-3 parts of orange 4, 0.5-0.8 part of red 28, and 0.1-0.2 part of iron black. The fullerene color-changing lipstick provided by the invention is easy to spread, easily develops color, has a good makeup holding effect without lip balm primer, has anti-inflammatory effects, effectively alleviates cleft lip, has no obvious lip lines, modifies lip contour, makes a lip appear a full and soft state, and is very translucent.

Disclosed is a novel synthesis and cross-linking method which can completely degrading intraosseous fixed polymer. The invention adopts 1, 2-propylene glycol (or ethylene glycol ), dineopentyl alcohol neopentyl glycol, maleic anhydride, phthalic anhydride, glycin (or caprolactam) and cyclohexanol as raw material to synthesize an adjustable, innocuous, low-cost unsaturated polyesteramide, by a method of melt phase polycondensation and molecular chain end capping. By adding an amount of crosslinking agent (vinyl acetate or vinyl pyrrolidone) and initiating heat treatment after the accelerant crosslinking at room temperature, the completely degradable intraosseous fixed material with high strength can be produced. The unsaturated polyesteramide can also be developed into completely-degradable disposable tablewares, packing materials, flowerpots, medical supplies, drug-coating or basis materials such as delayed (controlled) release materials for capsules and drugs, glass fiber reinforced plastics etc.

The invention relates to a preparation method for 4-azaspiro [2.4] heptane hydrochloride and mainly aims to solve the technical problem that a suitable industrial synthesis method does not exist at present. The preparation method comprises the following steps of: firstly, preparing 4-benzyl-4-azaspiro [2.4] heptane by taking 1-benzylpyrrolidine-2-ketone and an ethylmagnesium bromide reagent as raw materials, and then, preparing the 4-azaspiro [2.4] heptane hydrochloride by using chloroethyl chloroformate. The reaction formula is shown as follows: the 4-azaspiro [2.4] heptane hydrochloride obtained by the preparation method is a useful midbody or product used for synthesizing plenty of drugs.

The present invention relates to the technical field of veterinary pharmaceuticals, and specifically relates to an unilateral mequindox injection and a preparation method thereof. The unilateral mequindox injection comprises the following feed compositions in mass concentrations: mequindox 18-22g/L; ethanol 180-220g/L; propylene glycol 90-110g/L; alpha-pyrrolidone 280-320g/L; and water for injection as a solvent. Compared to the prior art, sodium salicylate is removed from production process of the unilateral mequindox injection in the present invention, so as to obtain an injection product with stability comparable to an original injection, and maximum absorption can be detected at 242, 254 and 371 nm of wavelength, thereby ensuring quality of the product and meeting provisions in mequindox injection identification (2) section in Quality Standards for Veterinary Medicines, 2017 Edition, Chemicals Volume.

The invention discloses a sildenafil citrate composition and a preparation method thereof, and belongs to the technical field of medicines. The sildenafil citrate composition takes sildenafil citrateas a main drug, and takes povidone K30, crospovidone, a vinyl pyrrolidone-vinyl acetate copolymer, xanthan gum, crosslinked carboxyl cellulose sodium, hydroxypropyl cellulose, triethyl citrate, tributyl citrate, dibutyl sebacate, diethyl phthalate, magnesium stearate and the like as auxiliary materials. Compared with those in the prior art, sildenafil citrate tablets or capsules obtained by adopting a hot-melt extrusion technology are simple and convenient to operate, environment-friendly, simple in prescription and suitable for large-scale production and application; and compared with preparations in the market, the obtained sildenafil citrate tablets or capsules are high in dissolution rate, good in stability, low in impurity content and high in clinical application safety.

The invention discloses a dimethylcurcumin solid dispersoid as well as a preparation method and application thereof, and relates to the field of pharmaceutic preparations. The dimethylcurcumin solid dispersoid is formed by dimethylcurcumin and a water-soluble carrier material, wherein the water-soluble carrier material comprises PEG4000, PEG6000, polyvinylpyrrolidone (PVP K30), and poloxamer 188.The dimethylcurcumin solid dispersoid is prepared by using a melting method or a solvent method. An indissoluble drug of the dimethylcurcumin is prepared as the solid dispersoid. A dissolution rate, dispersity, solubility and bioavailability of the drug are improved. The solid dispersoid can be further prepared as solid preparations of a tablet, a capsule and the like. The dimethylcurcumin solid dispersoid is simple in preparation process, cheap in price, and easy to industrialization.

The invention relates to a preparation method of a compound high-efficiency anticoccidial medicine sulfachloropyrazine sodium and diaveridine solution. The solution is provided mainly for overcoming defects such as mixing difficulty, inconvenient dosing, inaccurate dose, and the like of existing powders. The solution comprises main components of: main medicines of sulfachloropyrazine sodium and diaveridine, and auxiliary materials of dimethyl sulfoxide, N-methylpyrrolidone, a cosolvent, and triethanolamine. A preparation process provided by the invention comprises the steps that: dimethyl sulfoxide, N-methylpyrrolidone, and sulfachloropyrazine sodium are dissolved in a liquid blending tank; diaveridine well dissolved by the cosolvent is added; and triethanolamine with a formulated dose is added. The method has the advantages of simple production process, stable product quality, simple feeding method, and accurate dose.

The invention provides a Tianshu dispersible tablet for treating headaches, a preparation method and a quality control method. Magnesium stearate and aspartame are prepared; compared with the prior art, the dispersible tablet of the present invention has the following advantages: the disintegration time is short, and the dispersion state is good; the medicine dissolves rapidly, absorbs quickly, and has high bioavailability; The production equipment is the same as that of ordinary tablets, which is suitable for large-scale industrial production; it is convenient to take and has various methods, especially suitable for the elderly, young and patients with difficulty swallowing; it is convenient to produce, carry, and transport, and the quality is stable. In addition, the quality control method of the present invention has high precision, good reproducibility and accurate measurement results, which can effectively guarantee the clinical curative effect of the preparation.

The invention discloses an application of a ferroptosis-targeting nano-drug in treatment of acute kidney injury. Gallium gallate polyvinylpyrrolidone nanoparticles (GGP NPs) are synthesized in the invention, and the nanoparticles have strong stability, excellent biocompatibility and effective iron substitution ability. The GGP NPs has the advantages that accumulation of free iron in cells and mitochondrial dysfunction are reduced, ferroptosis-mediated phenotypes including lipid peroxidation, NADPH (nicotinamide adenine dinucleotide phosphate) and glutathione levels and glutathione peroxidase 4 activity are inhibited, and accordingly the HK-2 cell ferroptosis induced by cis-platinum can be obviously inhibited. The GGP NPs treatment can significantly improve renal tubule injury and mitochondrial injury caused by cisplatin treatment or ischemia reperfusion injury. The GGP NPs synthesized by the invention may be an effective and promising candidate drug for AKI treatment.

The present invention relates to a cosmetic composition comprising, in a physiologically acceptable medium, an oily phase and at least a) a phenyl silicone oil of formula (I) [Chemical Formula 1] (I) wherein-Me is methyl, Ph is phenyl, oR'represents a-OSiMe3 group,-y ranges from 1 to 1000, and-z ranges from 1 to 1000, b) a C8-C30 fatty alcohol, c) a branched dextrin ester, and d) advantageously a fat-soluble polymer selected from the group consisting of (i) acrylate polymers selected from the group consisting of silicon acrylate polymers, acrylate polymers comprising an alkyl chain of at least 10 carbon atoms, and copolymers of acrylates and acrylamides, the present invention relates to a cosmetic composition comprising (i) a copolymer of vinyl pyrrolidone (VP) and an olefin having at least 18 carbon atoms, (ii) a copolymer of vinyl pyrrolidone (VP) and an olefin having at least 18 carbon atoms, and (iii) mixtures thereof, and the use thereof for improving gloss and a more lasting cosmetic result of gloss and colour, in particular for lips. Preferably, the composition is in a semi-solid or solid form.

The invention relates to a new crystal form A of trans-4-phenyl-5-o-chlorobenzylpyrrolidone-2, as well as a medicine composition comprising the crystal form and application thereof. The crystal form Acan be used for preparing medicines such as high-selective calcium antagonists and medicines for improving disordered brain function, resisting Alzheimer's disease and depression, and enhancing learning and memory capability. The preparation method of the trans-4-phenyl-5-o-chlorobenzylpyrrolidone-2 crystal form A is simple in operation and is controllable in crystallization process. The producthas high crystallization degree and good repeatability, and can be absorbed and utilized by body better.

The invention provides a pramipexole tablet preparation method. The method comprises the following steps: suspending starch in a solvent, fully swelling, dispersing and stirring, filtering, and drying; sieving pramipexole, starch, mannitol, silica and magnesium stearate, fully mixing pramipexole with starch according to an equivalent progressive maximum process; and sequentially adding mannitol and an ethanol solution of polyvinylpyrrolidone, granulating, drying, and adding magnesium stearate and silica. The invention also provides a pramipexole tablet prepared through the preparation method, and an application of the pramipexole tablet in the preparation of medicines for treating the Parkinson's disease and restless legs syndrome. The content of related substances in the pramipexole tablet is less than 0.5%. The pramipexole tablet prepared through the method contains few types of the related substances, and has an obviously reduced content of total impurities.